|
1
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barrena Medel NI, Bansal S, Miller DS,
Wright JD and Herzog TJ: Pharmacotherapy of endometrial cancer.
Expert Opin Pharmacother. 10:1939–1951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Einbond A and Sudol M: Towards prediction
of cognate complexes between the WW domain and proline-rich
ligands. FEBS Lett. 384:1–8. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sudol M, Chen HI, Bougeret C, Einbond A
and Bork P: Characterization of a novel protein-binding module -
the WW domain. FEBS Lett. 369:67–71. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Doong H, Vrailas A and Kohn EC: What’s in
the ‘BAG’? - A functional domain analysis of the BAG-family
proteins. Cancer Lett. 188:25–32. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Doong H, Price J, Kim YS, Gasbarre C,
Probst J, Liotta LA, Blanchette J, Rizzo K and Kohn E: CAIR-1/BAG-3
forms an EGF-regulated ternary complex with phospholipase C-gamma
and Hsp70/Hsc70. Oncogene. 19:4385–4395. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iwasaki M, Homma S, Hishiya A, Dolezal SJ,
Reed JC and Takayama S: BAG3 regulates motility and adhesion of
epithelial cancer cells. Cancer Res. 67:10252–10259. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suzuki M, Iwasaki M, Sugio A, Hishiya A,
Tanaka R, Endo T, Takayama S and Saito T: BAG3 (BCL2-associated
athanogene 3) interacts with MMP-2 to positively regulate invasion
by ovarian carcinoma cells. Cancer Lett. 303:65–71. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: Past, present, and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Banno K, Yanokura M, Kisu I, Yamagami W,
Susumu N and Aoki D: MicroRNAs in endometrial cancer. Int J Clin
Oncol. 18:186–192. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Devor EJ, Hovey AM, Goodheart MJ,
Ramachandran S and Leslie KK: microRNA expression profiling of
endometrial endometrioid adenocarcinomas and serous adenocarcinomas
reveals profiles containing shared, unique and differentiating
groups of microRNAs. Oncol Rep. 26:995–1002. 2011.PubMed/NCBI
|
|
13
|
Hiroki E, Akahira J, Suzuki F, Nagase S,
Ito K, Suzuki T, Sasano H and Yaegashi N: Changes in microRNA
expression levels correlate with clinicopathological features and
prognoses in endometrial serous adenocarcinomas. Cancer Sci.
101:241–249. 2010. View Article : Google Scholar
|
|
14
|
Garzon R, Heaphy CE, Havelange V, et al:
MicroRNA 29b functions in acute myeloid leukemia. Blood.
114:5331–5341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sugio A, Iwasaki M, Habata S, Mariya T,
Suzuki M, Osogami H, Tamate M, Tanaka R and Saito T: BAG3
upregulates Mcl-1 through downregulation of miR-29b to induce
anticancer drug resistance in ovarian cancer. Gynecol Oncol.
134:615–623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mott JL, Kobayashi S, Bronk SF and Gores
GJ: miR-29 regulates Mcl-1 protein expression and apoptosis.
Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fang JH, Zhou HC, Zeng C, Yang J, Liu Y,
Huang X, Zhang JP, Guan XY and Zhuang SM: MicroRNA-29b suppresses
tumor angiogenesis, invasion, and metastasis by regulating matrix
metalloproteinase 2 expression. Hepatology. 54:1729–1740. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Homma S, Iwasaki M, Shelton GD, Engvall E,
Reed JC and Takayama S: BAG3 deficiency results in fulminant
myopathy and early lethality. Am J Pathol. 169:761–773. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stetler-Stevenson WG, Aznavoorian S and
Liotta LA: Tumor cell interactions with the extracellular matrix
during invasion and metastasis. Annu Rev Cell Biol. 9:541–573.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ogasawara S, Yano H, Momosaki S, Nishida
N, Takemoto Y, Kojiro S and Kojiro M: Expression of matrix
metalloproteinases (MMPs) in cultured hepatocellular carcinoma
(HCC) cells and surgically resected HCC tissues. Oncol Rep.
13:1043–1048. 2005.PubMed/NCBI
|
|
21
|
Giannelli G, Bergamini C, Marinosci F,
Fransvea E, Quaranta M, Lupo L, Schiraldi O and Antonaci S:
Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular
carcinoma. Int J Cancer. 97:425–431. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Negrini M, Ferracin M, Sabbioni S and
Croce CM: MicroRNAs in human cancer: From research to therapy. J
Cell Sci. 120:1833–1840. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Steele R, Mott JL and Ray RB: MBP-1
upregulates miR-29b that represses Mcl-1, collagens, and
matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer.
1:381–387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Zhang X, Li H, Yu J and Ren X: The
role of miRNA-29 family in cancer. Eur J Cell Biol. 92:123–128.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gebeshuber CA, Zatloukal K and Martinez J:
miR-29a suppresses tristetraprolin, which is a regulator of
epithelial polarity and metastasis. EMBO Rep. 10:400–405. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mott JL, Kurita S, Cazanave SC, Bronk SF,
Werneburg NW and Fernandez-Zapico ME: Transcriptional suppression
of miR-29b-1/miR-29a promoter by c-Myc, hedgehog, and NF-kappaB. J
Cell Biochem. 110:1155–1164. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang H, Garzon R, Sun H, et al:
NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis
and rhabdomyosarcoma. Cancer Cell. 14:369–381. 2008. View Article : Google Scholar : PubMed/NCBI
|
